NASDAQ:BYSI

BeyondSpring Competitors

$10.29
-0.33 (-3.11 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.15
Now: $10.29
$10.75
50-Day Range
$10.27
MA: $12.26
$14.92
52-Week Range
$9.83
Now: $10.29
$21.50
Volume140,238 shs
Average Volume275,148 shs
Market Capitalization$402.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6

Competitors

BeyondSpring (NASDAQ:BYSI) Vs. TVTX, ZNTL, GBIO, KRON, QURE, and HRTX

Should you be buying BYSI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BeyondSpring, including Travere Therapeutics (TVTX), Zentalis Pharmaceuticals (ZNTL), Generation Bio (GBIO), Kronos Bio (KRON), uniQure (QURE), and Heron Therapeutics (HRTX).

BeyondSpring (NASDAQ:BYSI) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and Travere Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeyondSpringN/A-221.67%-139.97%
Travere Therapeutics-40.24%-29.27%-12.25%

Valuation & Earnings

This table compares BeyondSpring and Travere Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpringN/AN/A$-38,080,000.00($1.55)-6.64
Travere Therapeutics$175.34 million8.83$-146,430,000.00($3.46)-7.40

BeyondSpring has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

BeyondSpring has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Travere Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeyondSpring01202.67
Travere Therapeutics00403.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Travere Therapeutics has a consensus target price of $47.00, suggesting a potential upside of 83.52%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Travere Therapeutics.

Summary

Travere Therapeutics beats BeyondSpring on 7 of the 13 factors compared between the two stocks.

BeyondSpring (NASDAQ:BYSI) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeyondSpringN/A-221.67%-139.97%
Zentalis PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares BeyondSpring and Zentalis Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpringN/AN/A$-38,080,000.00($1.55)-6.64
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Comparatively, 67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Zentalis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeyondSpring01202.67
Zentalis Pharmaceuticals00703.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Zentalis Pharmaceuticals has a consensus target price of $54.2857, suggesting a potential upside of 45.11%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Zentalis Pharmaceuticals.

Summary

Zentalis Pharmaceuticals beats BeyondSpring on 5 of the 6 factors compared between the two stocks.

BeyondSpring (NASDAQ:BYSI) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and Generation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeyondSpringN/A-221.67%-139.97%
Generation BioN/AN/AN/A

Valuation & Earnings

This table compares BeyondSpring and Generation Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpringN/AN/A$-38,080,000.00($1.55)-6.64
Generation BioN/AN/AN/AN/AN/A

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Comparatively, 63.3% of Generation Bio shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Generation Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeyondSpring01202.67
Generation Bio00603.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Generation Bio has a consensus target price of $40.60, suggesting a potential upside of 49.26%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Generation Bio.

Summary

Generation Bio beats BeyondSpring on 5 of the 6 factors compared between the two stocks.

BeyondSpring (NASDAQ:BYSI) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeyondSpringN/A-221.67%-139.97%
Kronos BioN/AN/AN/A

Valuation & Earnings

This table compares BeyondSpring and Kronos Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpringN/AN/A$-38,080,000.00($1.55)-6.64
Kronos BioN/AN/AN/AN/AN/A

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Kronos Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeyondSpring01202.67
Kronos Bio00403.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 60.07%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Kronos Bio.

Summary

Kronos Bio beats BeyondSpring on 4 of the 6 factors compared between the two stocks.

BeyondSpring (NASDAQ:BYSI) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and uniQure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeyondSpringN/A-221.67%-139.97%
uniQure-2,738.33%-59.64%-41.47%

Valuation & Earnings

This table compares BeyondSpring and uniQure's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpringN/AN/A$-38,080,000.00($1.55)-6.64
uniQure$7.28 million208.53$-124,200,000.00($3.11)-10.85

BeyondSpring has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Comparatively, 78.3% of uniQure shares are held by institutional investors. 2.8% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

BeyondSpring has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and uniQure, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeyondSpring01202.67
uniQure011113.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. uniQure has a consensus target price of $68.4615, suggesting a potential upside of 102.91%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than uniQure.

Summary

uniQure beats BeyondSpring on 9 of the 14 factors compared between the two stocks.

BeyondSpring (NASDAQ:BYSI) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Heron Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeyondSpring01202.67
Heron Therapeutics01502.83

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Heron Therapeutics has a consensus target price of $29.60, suggesting a potential upside of 78.31%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Heron Therapeutics.

Profitability

This table compares BeyondSpring and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeyondSpringN/A-221.67%-139.97%
Heron Therapeutics-216.18%-65.06%-49.14%

Valuation & Earnings

This table compares BeyondSpring and Heron Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpringN/AN/A$-38,080,000.00($1.55)-6.64
Heron Therapeutics$145.97 million10.39$-204,750,000.00($2.50)-6.64

BeyondSpring has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Comparatively, 99.0% of Heron Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

BeyondSpring has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Summary

Heron Therapeutics beats BeyondSpring on 8 of the 13 factors compared between the two stocks.


BeyondSpring Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
News Coverage
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88Gap Down
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58-0.5%$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38-8.0%$1.15 billionN/A-8.88High Trading Volume
News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54-1.6%$1.14 billionN/A0.00Unusual Options Activity
Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78-0.7%$1.14 billionN/A0.00News Coverage
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81-1.8%$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50-1.4%$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42-7.3%$1.07 billion$120,000.00-3.86News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57-1.3%$1.07 billionN/A-8.82Analyst Report
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16-2.8%$1.07 billion$1.52 million-11.79News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27-1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28-1.6%$1.06 billionN/A0.00News Coverage
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27News Coverage
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25-1.9%$922.56 millionN/A0.00
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.